West Pharmaceutical Services (NYSE:WST) Releases Quarterly Earnings Results

West Pharmaceutical Services (NYSE:WST) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.45, Zacks reports. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The company had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.68 million. During the same quarter in the prior year, the firm earned $1.45 earnings per share. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. West Pharmaceutical Services updated its FY 2026 guidance to 8.400-8.750 EPS and its Q2 2026 guidance to 2.050-2.120 EPS.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

• West reported a strong Q1 with revenues of $845M (+21% reported, +15% organic) and adjusted EPS of $2.13, and raised full‑year guidance to 7%–9% organic revenue growth and $8.40–$8.75 adjusted EPS.
• HVP components remain the main growth engine—organic HVP components growth was ~23%, GLP‑1s represented ~10% of company sales, biologics were up 26%, and Annex I / HVP conversion is expected to add ~200 bps to revenue growth in 2026.
• Margins and capital returns improved: adjusted operating margin expanded to 21.4% ( +350 bps Y/Y), the board authorized a $1B share buyback and the company repurchased $298M of shares in Q1.
• Near‑term headwinds include a ~$40M CGM contract roll‑off in H2, and rising oil/commodity costs (management expects a net impact of low‑single‑digit millions after mitigation), which could pressure second‑half cadence and margins.

West Pharmaceutical Services Price Performance

WST opened at $309.25 on Friday. The business has a fifty day moving average of $252.00 and a 200 day moving average of $262.10. The stock has a market cap of $22.29 billion, a P/E ratio of 45.54, a PEG ratio of 2.92 and a beta of 1.15. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06. West Pharmaceutical Services has a 52-week low of $199.89 and a 52-week high of $322.34.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Wednesday, April 29th. West Pharmaceutical Services’s payout ratio is currently 12.96%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 14th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $315.00 price objective on shares of West Pharmaceutical Services in a research note on Friday, February 13th. UBS Group reissued a “buy” rating and issued a $340.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Jefferies Financial Group reaffirmed a “buy” rating and set a $295.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Finally, Barclays boosted their price objective on shares of West Pharmaceutical Services from $265.00 to $275.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and a consensus price target of $315.67.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q1 beat: West reported EPS of $2.13 vs. consensus $1.68 and revenue of $844.9M vs. ~$779.7M, with revenue up ~21% year-over-year — a clear operational beat that validates growth momentum. Earnings Call Transcript
• Positive Sentiment: Raised guidance: Management increased FY2026 EPS guidance to $8.40–$8.75 (vs. prior consensus ~7.99) and Q2 EPS to $2.05–$2.12, signaling confidence in continued demand and margin improvement. Reuters: Forecast Lift
• Positive Sentiment: Product-driven growth and margins: Analysts and company commentary highlight strong demand for proprietary packaging (syringes, cartridges and high-volume components), which supported both top-line beat and margin expansion in the quarter. Yahoo: Q1 Highlights
• Neutral Sentiment: Market reaction framing: Multiple outlets note the stock “soared” on the results and guidance; investors should watch the upcoming quarterly cadence and execution against raised targets for confirmation. Seeking Alpha: Market Reaction
• Neutral Sentiment: Company materials available: Press release, slide deck and call transcript provide detail on segment performance and customer demand — useful for modeling FY uplift and margin assumptions. Slide Deck / Press Release
• Negative Sentiment: Valuation and execution risk: The shares trade at a premium P/E; the stock’s move partially prices in continued HVP demand and margin gains — missing elevated guidance later would risk a sharp pullback. Zacks: Analyst Note

Institutional Investors Weigh In On West Pharmaceutical Services

A number of institutional investors and hedge funds have recently bought and sold shares of WST. Aptus Capital Advisors LLC increased its holdings in shares of West Pharmaceutical Services by 5.5% in the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after acquiring an additional 47 shares during the period. IFM Investors Pty Ltd increased its position in shares of West Pharmaceutical Services by 0.4% in the 4th quarter. IFM Investors Pty Ltd now owns 13,730 shares of the medical instruments supplier’s stock valued at $3,778,000 after acquiring an additional 49 shares during the period. Benjamin Edwards Inc. lifted its position in West Pharmaceutical Services by 1.7% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier’s stock worth $661,000 after acquiring an additional 50 shares during the period. Smartleaf Asset Management LLC grew its stake in West Pharmaceutical Services by 4.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,207 shares of the medical instruments supplier’s stock valued at $334,000 after purchasing an additional 53 shares during the last quarter. Finally, Caerus Investment Advisors LLC increased its holdings in shares of West Pharmaceutical Services by 6.2% in the fourth quarter. Caerus Investment Advisors LLC now owns 1,035 shares of the medical instruments supplier’s stock valued at $285,000 after purchasing an additional 60 shares during the period. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services announced that its board has initiated a stock buyback program on Tuesday, February 17th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical instruments supplier to buy up to 5.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.